FOLH1 and posterior cortical atrophy: Patients who have received less than six doses of [177Lu]Lu-PSMA-617 may be re-treated with [177Lu]Lu-PSMA-617 upon disease progression with symptomatic disease from PCa, PSA progression by PCWG3 recommendation, or radiological progression.